BPTH: Bio-Path Holdings Inc. Company Value to Net Income

Bio-Path - graphic logo of issuer BPTH

Bio-Path Holdings (BPTH) develops unique liposomal DNA therapies for leukemia, leveraging a robust scientific and technical foundation. The business's profitability is based on future licensing agreements and deals with insurance companies. However, a narrow development focus creates binary risks dependent on test results. This historical price chart confirms these data, with the current indicator standing at -0.10.

BPTH - biopathholdings.com Price to Earnings Ratio over the range 07/04/2022 - 02/22/2025

Analytical breakdowns for Bio-Path Holdings

- share price and expert price forecast:
Price Performance Chart biopathholdings.com|BPTH - Consensus Target
- market capitalization information:
Market Value Bio-Path Holdings, Inc.|BPTH - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Bio-Path Holdings|BPTH - Company Book Value|Market Value to Book Value Ratio biopathholdings.com|BPTH - Aggregate Company Assets
- debt and solvency information:
Debt to Capital Bio-Path Holdings|BPTH - Long-Term Debt to Equity|Current Liabilities to Capital Bio-Path Holdings, Inc|BPTH - Company Aggregate Debts|Debt to Book Value Ratio Bio-Path Holdings, Inc.|BPTH - Company Long-Term Debts|Company Short-Term Debt Bio-Path Holdings|Interim Coverage Ratio biopathholdings.com
- earnings and market ratios statistics:
BPTH - Company Net Income|Expected Net Profit Bio-Path Holdings|BPTH - Price to Earnings Ratio|Forward Price to Earnings Multiple Bio-Path Holdings Inc.|BPTH - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Bio-Path Holdings, Inc.|BPTH - Operating profit EBITDA|Net earnings per share (EPS TTM) Bio-Path Holdings|BPTH - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months biopathholdings.com|BPTH - Earnings growth in current year|Expected earnings per share trend next year Bio-Path Holdings
Summary company analysis:biopathholdings.com BPTH
Original product of Bio-Path Holdings, Inc.

The performance dynamics of Bio-Path Holdings (BPTH) are reflected through the P/E ratio, which compares the company's market value to its net income. This coefficient measures the cost of one dollar of current earnings, indicating the degree of the asset's overvaluation. The calculation is based on dividing market capitalization by annual income. For an oncology startup, the absence of profit turns this metric into an indicator of expectations for future unique technology. It is critical for investors to assess this figure as a measure of the speculative premium for the potential success of the drugs.

Key competitors

TGTX: Company Value to Net Income|Price to Earnings Ratio ACLX (Arcellx, Inc.)|IRON (Disc Medicine Inc) - Company Value to Net Income|P/E Multiple SNDX (Syndax)|Kura - Price to Earnings Ratio|ADCT - Price to Earnings Ratio|FHTX: Price to Earnings Ratio|Vor Biopharma (VOR) - Price to Earnings Ratio|Market Cap to Earnings Nkarta (NKTX)|Price to Earnings Ratio Coeptis Therapeutics Inc.|Market Cap to Earnings Actinium Corp ATNM|P/E Multiple ESLA|casipharmaceuticals.com - Price to Earnings Multiple|P/E Multiple MRKR (Marker Therapeutics, Inc.)|IN8bio Inc. - Price to Earnings Ratio|Eterna Therapeutics Inc - P/E Multiple|Business Payback Period GT Biopharma Corporation GTBP|aptose.com (APTO) - Price to Earnings Ratio|Market Cap to Earnings meipharma.com (MEIP)|Price to Earnings Ratio VINC